Sirona Biochem Signs International Partnership Agreement with Wanbang Biopharmaceuticals

Posted: November 24, 2022 at 12:17 am

VANCOUVER, British Columbia, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) announces that, subsequent to the LOI, Sirona and Wanbang Biopharmaceuticals (“Wanbang”) have signed an expanded, international partnership agreement to collaborate on licencing Sirona’s SGLT2 inhibitor, TFC-039, as a pharmaceutical treatment in both animal and human health. The agreement adds human health to the partnership as a result of new licencing opportunities currently in due diligence.

More:
Sirona Biochem Signs International Partnership Agreement with Wanbang Biopharmaceuticals

Related Posts